Cytokinetics touts data from heart failure trial

A small mid-stage study has produced positive interim data for Cytokinetics' experimental drug CK-1827452. A full set of data will be delivered to Amgen--which has an option to co-develop the drug--by the end of the year. The developer is pursuing clinical research of the drug's effect on stable heart failure patients, evaluating CK-1827452 for the potential treatment of patients with either acutely decompensated or chronic heart failure. Cytokinetocs announced just a week ago that it was axing a third of its staff so it could concentrate more of its resources to advance CK-1827452.

"The unique mechanism of action of CK-1827452 increases stroke volume without an increase in energy expenditure and holds great promise for the treatment of heart failure," said Dr. John Cleland, professor of cardiology at the UK's Castle Hill Hospital, University.

The interim analyses demonstrated statistically significant correlations between CK-1827452 plasma concentration and increases in systolic ejection time, stroke volume, fractional shortening (each p < 0.0001), cardiac output (p < 0.01), and ejection fraction (p < 0.05).

- check out the Cytokinetics release

RelaCytokineticsted Articles:
Cytokinetics slashes workforce, drops oncology work
Cytokinetics extends GSK collaboration
Cytokinetics forges $75M financing deal